Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29479871 | 1.00 | SLC9A1 (0.64) | SLC9A1KMT2AMAPK1CYP2C19MEN1 | |
| SCHEMBL16974408 | 0.84 | KMT2A (0.70) | SLC9A1KMT2AMAPK1CYP2C19MEN1 | |
| SCHEMBL11428076 | 0.84 | SLC9A1 (0.50) | SLC9A1KMT2AMAPK1CYP2C19MEN1 | |
| SCHEMBL18062179 | 0.81 | SLC9A1 (0.64) | SLC9A1KMT2AMAPK1CYP2C19MEN1 | |
| SCHEMBL22494210 | 0.81 | SLC9A1 (0.64) | SLC9A1KMT2AMAPK1CYP2C19MEN1 | |
| SCHEMBL3079415 | 0.81 | SLC9A1 (0.64) | SLC9A1KMT2AMAPK1CYP2C19MEN1 | |
| SCHEMBL2181249 | 0.80 | SLC9A1 (0.58) | SLC9A1KMT2AMAPK1CYP2C19MEN1 | |
| SCHEMBL20621852 | 0.80 | SLC9A1 (0.58) | SLC9A1KMT2AMAPK1CYP2C19MEN1 | |
| SCHEMBL28947521 | 0.80 | SLC9A1 (0.58) | SLC9A1KMT2AMAPK1CYP2C19MEN1 | |
| SCHEMBL3921769 | 0.80 | SLC9A1 (0.58) | SLC9A1KMT2AMAPK1CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2644597-B1 | Novel method for synthesising ivabradine and its pharmaceutically acceptable acid addition salts | SERVIER LAB (FR) | 2016-01-13 | — | — | EP | claimed |
| CN-103450082-B | The novel method of the additive salt of synthesis of ivabradine and itself and pharmaceutically acceptable acid | LABORATOIRES THERWILL (FR) | 2015-11-18 | — | — | CN | claimed |
| US-8853276-B2 | Guanidine derivatives in cinnamic series | PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) | 2014-10-07 | — | — | US | claimed |
| US-8835627-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2014-09-16 | — | — | US | claimed |
| EP-2614046-B1 | NOVEL GUANIDINE DERIVATIVES IN THE CINNAMIC SERIES | PROD CHIM AUXILIAIRES ET DE SYNTHESE (FR) | 2014-08-20 | — | — | EP | claimed |
| CN-103450082-A | Novel method for synthesising ivabradine and its pharmaceutically acceptable acid addition salts | SERVIER LAB | 2013-12-18 | — | — | CN | claimed |
| US-20130261298-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2013-10-03 | — | — | US | claimed |
| EP-2644597-A1 | Novel method for synthesising ivabradine and its pharmaceutically acceptable acid addition salts | Les Laboratoires Servier (FR) | 2013-10-02 | — | — | EP | claimed |
| EP-2614046-A1 | NOVEL GUANIDINE DERIVATIVES IN THE CINNAMIC SERIES | Produits Chimiques Auxiliaires et de Synthese (FR) | 2013-07-17 | — | — | EP | claimed |
| US-20130165507-A1 | NEW GUANIDINE DERIVATIVES IN CINNAMIC SERIES | PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) | 2013-06-27 | — | — | US | claimed |
| WO-2012032257-A1 | NOVEL GUANIDINE DERIVATIVES IN THE CINNAMIC SERIES | PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) | 2012-03-15 | — | — | WO | claimed |
| EP-2014797-A2 | Coating composition for interconnection part of electrode and plasma display panel including the same | Samsung SDI Co., Ltd. (KR) | 2009-01-14 | — | — | EP | claimed |
| US-20080303439-A1 | Coating composition for interconnection part of electrode and plasma display panel including the same | SAMSUNG SDI CO., LTD., A CORP. OF THE REPUBLIC OF KOREA (KR) | 2008-12-11 | — | — | US | claimed |
| US-12534474-B2 | Dihydrofuropyridine derivatives as rho-kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-01-27 | — | — | US | disclosed |
| EP-4263547-B1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2025-07-02 | — | — | EP | disclosed |
| EP-4263546-B1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2025-07-02 | — | — | EP | disclosed |
| EP-1180722-A2 | Photothermographic materials providing improved image stability and methods of use | EASTMAN KODAK COMPANY (US) | 2002-02-20 | — | — | EP | disclosed |
| US-6171767-B1 | BLACK-AND-WHITE PHOTOTHERMOGRAPHIC ELEMENT WITH AN IMAGING COATING COMPRISING PHOTOSENSITIVE SILVER HALIDE, REDUCIBLE SILVER SOURCE, REDUCING AGENT, BINDER, BENZOTRIAZOLE COMPOUND | EASTMAN KODAK COMPANY | 2001-01-09 | — | — | US | disclosed |
| EP-1048975-A1 | 1-sulfonyl-1H-benzotriazole compounds as print stabilizers in photothermographic elements | EASTMAN KODAK COMPANY (US) | 2000-11-02 | — | — | EP | disclosed |
| US-4211839-A | SILVER HALIDE AND ORGANIC SILVER SALT PREPARED IN AN IMINO COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1980-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165507-A1 | NEW GUANIDINE DERIVATIVES IN CINNAMIC SERIES | GMPS, UNG, AGER | SLC9A1 4061/4885KMT2A 3270/4885MAPK1 1776/4885 |
| US-12534474-B2 | Dihydrofuropyridine derivatives as rho-kinase inhibitors | ROCK1, RHOC, ROCK2 | SLC9A1 1050/4885KMT2A 3981/4885MAPK1 119/4885 |
| US-20130261298-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | CYP4F2, CYP2F1, CYP2D6 | SLC9A1 169/4885KMT2A 2674/4885MAPK1 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.